10-Year Survival Rate for Melanoma Patients Using Opdivo-Yervoy Combination

Monday, 16 September 2024, 07:40

Survival rate for melanoma therapy shows promising results, with 43% of patients alive after 10 years on the Opdivo-Yervoy combo. New data revealed indicates this dual treatment significantly improves outcomes for advanced melanoma. At the recent ESMO Congress, Bristol Myers Squibb highlighted the transformative impact of their combination therapy on survival rates.
LivaRava_Health_Default_2.png
10-Year Survival Rate for Melanoma Patients Using Opdivo-Yervoy Combination

Transformative Results for Melanoma Treatment

In a groundbreaking revelation at the European Society for Medical Oncology (ESMO) Congress, Bristol Myers Squibb (BMS) announced that the long-term survival rate for patients with advanced melanoma utilizing the combination therapy of Opdivo and Yervoy stands at an impressive 43% after a decade. This marks a monumental shift from previous survival statistics that reported only about 25% of melanoma patients surviving their first year.

Significant Findings from Long-Term Study

  • The median overall survival for patients receiving the combination therapy reached 71.9 months, representing the longest reported survival in a Phase III advanced melanoma trial.
  • In a statement, Dana Walker, VP at BMS, emphasized the dramatic changes in prognosis for these patients.
  • Among those who received Opdivo and Yervoy together, 64% did not require any subsequent systemic therapy after 10 years.

BMS Collaboration Changes

In addition to these findings, BMS announced a strategic decision to terminate its collaboration with Immatics concerning the bispecific T cell engager IMA401. As the biotech company moves forward, it will not have to refund the $150 million already allocated for this partnership.


Disclaimer: The information provided on this site is for informational purposes only and is not intended as medical advice. We are not responsible for any actions taken based on the content of this site. Always consult a qualified healthcare provider for medical advice, diagnosis, and treatment. We source our news from reputable sources and provide links to the original articles. We do not endorse or assume responsibility for the accuracy of the information contained in external sources.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Subscribe to our newsletter for the latest and most reliable health updates. Stay informed and enhance your wellness knowledge effortlessly.

Subscribe